Key Takeaways
- The strategic collaboration between Moffitt Cancer Center and AstraZeneca aims to accelerate the development of innovative oncology cell therapies, including CAR T and TCR T therapies, to improve cancer treatment options for patients globally.
- By leveraging Moffitt’s leading clinical expertise and AstraZeneca’s extensive pipeline of investigational therapies, the partnership seeks to expand the use of cell therapies in solid tumors and streamline the delivery of autologous cell therapies to patients.
- This collaboration underscores both organizations’ commitment to advancing cancer research and making cutting-edge, personalized cancer treatments more accessible and efficient for a wider patient population across the globe.
Moffitt Cancer Center announced a strategic partnership with AstraZeneca, aimed at accelerating the development and delivery of groundbreaking cell therapies in oncology, particularly focusing on chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR T) therapies. This collaboration is designed to leverage the unique strengths of both organizations, combining Moffitt’s leading clinical expertise with AstraZeneca’s extensive pipeline of investigational therapies, to significantly advance the field of cell-based cancer treatments.
Cell therapies like CAR T and TCR T have emerged as transformative treatments, offering new hope for cancers that have limited treatment options. Since the first CAR T therapies were approved by the FDA in 2017, the field has expanded rapidly, demonstrating tremendous potential to revolutionize cancer care. Moffitt Cancer Center has played an integral role in clinical trials that paved the way for several of these FDA approvals, and the institution continues to push the boundaries of cell therapy innovation, with a vast network of cancer centers and resources across the United States.
The partnership between Moffitt and AstraZeneca is poised to address key challenges in the development and scaling of cell therapies, focusing on expanding access to more patients globally. A primary objective will be to investigate and advance the use of CAR T and TCR T therapies in solid tumors, an area where research is still in its early stages but holds significant promise. Additionally, the collaboration will aim to optimize clinical operations, ensuring that autologous cell therapies—those derived from a patient’s cells—can be delivered to patients more efficiently and rapidly.
Moffitt Cancer Center and AstraZeneca Join Forces to Accelerate Groundbreaking Cell Therapies for Solid Tumors
“We are thrilled to collaborate with AstraZeneca, a leader in oncology innovation, to break new ground in cancer treatment,” said Patrick Hwu, M.D., president and CEO of Moffitt Cancer Center. “By combining our deep clinical expertise with AstraZeneca’s pipeline of investigational cell therapies, global reach, and leadership in the development of oncology treatments, we can accelerate the delivery of these cutting-edge therapies to patients who need them most. This partnership will allow us to explore new possibilities in cell therapy, particularly in solid tumors, which have remained a significant challenge in cancer treatment.”
The collaboration will give AstraZeneca priority access to Moffitt’s renowned clinical trial infrastructure, enabling the company to fast-track the investigation and development of novel cell therapies. Moffitt’s physician-scientists will work closely with AstraZeneca’s research teams to identify eligible patients and advance the clinical studies that could lead to breakthrough therapies.
For AstraZeneca, this partnership represents an important step in strengthening its oncology cell therapy pipeline, particularly in expanding its focus beyond hematological cancers to solid tumors. “This collaboration with Moffitt Cancer Center aligns perfectly with our vision to redefine cancer treatment for more people living with both hematological and solid tumors,” said Carsten Linnemann, Head of Oncology Cell Therapy Clinical Development at AstraZeneca. “By combining Moffitt’s cutting-edge clinical environment and expertise in cell therapy with AstraZeneca’s innovative therapeutic approaches, we aim to bring life-changing treatments to patients faster, providing new hope for those facing difficult-to-treat cancers.”
Moffitt and AstraZeneca Partner to Expand Global Access to Innovative Cancer Therapies and Accelerate Research
One of the core aspects of this partnership is the shared commitment to accelerating research and delivering innovative treatments that address the unmet needs of cancer patients worldwide. By integrating Moffitt’s pioneering work in personalized medicine and clinical trials with AstraZeneca’s global capabilities and investigational therapies, the collaboration seeks to broaden the reach of these transformative treatments, improving patient outcomes and advancing the frontier of cancer care.
This strategic alliance between Moffitt Cancer Center and AstraZeneca underscores both organizations’ dedication to pushing the limits of what is possible in oncology and contributing to the development of therapies that could reshape the future of cancer treatment. With a strong focus on collaboration, innovation, and patient access, the partnership is expected to drive significant advancements in the development of CAR T and TCR T therapies, making them available to a larger and more diverse patient population across the globe.
Through this partnership, Moffitt and AstraZeneca will work together to streamline the clinical trial process, accelerate regulatory approvals, and bring potentially life-saving treatments to patients with greater speed and efficiency, addressing some of the most pressing challenges in cancer treatment today.
Resource: Moffitt Cancer Center, September 13, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
